View ValuationCaplin Point Laboratories 将来の成長Future 基準チェック /26Caplin Point Laboratories利益と収益がそれぞれ年間11.8%と12.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に17% 11.9%なると予測されています。主要情報11.8%収益成長率11.88%EPS成長率Pharmaceuticals 収益成長16.1%収益成長率12.4%将来の株主資本利益率16.95%アナリストカバレッジLow最終更新日15 May 2026今後の成長に関する最新情報分析記事 • May 18Earnings Update: Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Just Reported Its Annual Results And Analysts Are Updating Their ForecastsIt's been a good week for Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) shareholders, because the company has...分析記事 • Nov 10₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These ResultsAs you might know, Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently reported its quarterly numbers. It was...Price Target Changed • Oct 11Price target increased by 14% to ₹2,142Up from ₹1,883, the current price target is an average from 3 analysts. New target price is 12% above last closing price of ₹1,906. Stock is up 72% over the past year. The company is forecast to post earnings per share of ₹67.78 for next year compared to ₹60.19 last year.分析記事 • Aug 11Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764Shareholders might have noticed that Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) filed its quarterly result...Price Target Changed • Aug 09Price target increased by 17% to ₹1,717Up from ₹1,472, the current price target is an average from 3 analysts. New target price is 14% above last closing price of ₹1,501. Stock is up 45% over the past year. The company is forecast to post earnings per share of ₹64.00 for next year compared to ₹60.19 last year.Price Target Changed • Nov 13Price target increased by 8.0% to ₹1,076Up from ₹996, the current price target is an average from 3 analysts. New target price is 17% below last closing price of ₹1,293. Stock is up 67% over the past year. The company is forecast to post earnings per share of ₹59.70 for next year compared to ₹49.62 last year.すべての更新を表示Recent updatesDeclared Dividend • May 16Final dividend increased to ₹4.00Dividend of ₹4.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 13th June 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (4% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • May 15Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: ₹84.36 (up from ₹70.57 in FY 2025). Revenue: ₹23.0b (up 19% from FY 2025). Net income: ₹6.41b (up 20% from FY 2025). Profit margin: 28% (in line with FY 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 3.7%. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 07Caplin Point Laboratories Limited to Report Q4, 2026 Results on May 14, 2026Caplin Point Laboratories Limited announced that they will report Q4, 2026 results on May 14, 2026分析記事 • Feb 12Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Share Price Not Quite Adding UpIt's not a stretch to say that Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...Board Change • Feb 10High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-executive Independent Director Susan Mathew was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹21.56 (vs ₹18.28 in 3Q 2025)Third quarter 2026 results: EPS: ₹21.56 (up from ₹18.28 in 3Q 2025). Revenue: ₹5.76b (up 17% from 3Q 2025). Net income: ₹1.64b (up 18% from 3Q 2025). Profit margin: 28% (in line with 3Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 27Caplin Point Laboratories Limited to Report Q3, 2026 Results on Feb 05, 2026Caplin Point Laboratories Limited announced that they will report Q3, 2026 results on Feb 05, 2026分析記事 • Dec 05Do Caplin Point Laboratories' (NSE:CAPLIPOINT) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Nov 09Getting In Cheap On Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is UnlikelyThere wouldn't be many who think Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...Reported Earnings • Nov 06Second quarter 2026 earnings released: EPS: ₹20.32 (vs ₹17.22 in 2Q 2025)Second quarter 2026 results: EPS: ₹20.32 (up from ₹17.22 in 2Q 2025). Revenue: ₹5.64b (up 17% from 2Q 2025). Net income: ₹1.54b (up 18% from 2Q 2025). Profit margin: 27% (in line with 2Q 2025). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 29Caplin Point Laboratories Limited to Report Q2, 2026 Results on Nov 05, 2025Caplin Point Laboratories Limited announced that they will report Q2, 2026 results on Nov 05, 2025分析記事 • Sep 16We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay RiseKey Insights Caplin Point Laboratories will host its Annual General Meeting on 22nd of September CEO Sridhar Ganesan's...Upcoming Dividend • Sep 05Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 12 September 2025. Payment date: 21 October 2025. Payout ratio is a comfortable 8.5% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%).分析記事 • Aug 31Do Caplin Point Laboratories' (NSE:CAPLIPOINT) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Declared Dividend • Aug 09Dividend of ₹3.00 announcedShareholders will receive a dividend of ₹3.00. Ex-date: 12th September 2025 Payment date: 21st October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (8% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 17% over the next year, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Aug 08First quarter 2026 earnings released: EPS: ₹20.10 (vs ₹16.32 in 1Q 2025)First quarter 2026 results: EPS: ₹20.10 (up from ₹16.32 in 1Q 2025). Revenue: ₹5.33b (up 16% from 1Q 2025). Net income: ₹1.53b (up 23% from 1Q 2025). Profit margin: 29% (up from 27% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 07Caplin Point Laboratories Limited, Annual General Meeting, Sep 22, 2025Caplin Point Laboratories Limited, Annual General Meeting, Sep 22, 2025.分析記事 • Aug 06Earnings Not Telling The Story For Caplin Point Laboratories Limited (NSE:CAPLIPOINT)NSEI:CAPLIPOINT 1 Year Share Price vs Fair Value Explore Caplin Point Laboratories's Fair Values from the Community and...お知らせ • Jul 30Caplin Point Laboratories Limited to Report Q1, 2026 Results on Aug 07, 2025Caplin Point Laboratories Limited announced that they will report Q1, 2026 results on Aug 07, 2025分析記事 • May 18Earnings Update: Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Just Reported Its Annual Results And Analysts Are Updating Their ForecastsIt's been a good week for Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) shareholders, because the company has...Declared Dividend • May 17Final dividend of ₹3.00 announcedShareholders will receive a dividend of ₹3.00. Ex-date: 30th May 2025 Payment date: 14th June 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (4% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 35% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • May 16Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: EPS: ₹70.57 (up from ₹60.20 in FY 2024). Revenue: ₹20.3b (up 20% from FY 2024). Net income: ₹5.36b (up 17% from FY 2024). Profit margin: 26% (in line with FY 2024). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 2.1%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 10Caplin Point Laboratories Limited to Report Fiscal Year 2025 Results on May 15, 2025Caplin Point Laboratories Limited announced that they will report fiscal year 2025 results on May 15, 2025お知らせ • Apr 22Caplin Point Laboratories Limited Announces Resignation of Thiagaraja Manikandan as Chief Transformation & Digital Officer, A Senior Management Personnel, Effective April 21, 2025Caplin Point Laboratories Limited announced that Mr. Thiagaraja Manikandan, Chief Transformation & Digital Officer, a Senior Management Personnel (SMP) of the Company, has resigned with effect from the close of working hours of April 21, 2025.分析記事 • Apr 14With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting CaseInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Apr 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹1,714, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 126% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹1,268 per share.Reported Earnings • Feb 08Third quarter 2025 earnings released: EPS: ₹18.28 (vs ₹15.44 in 3Q 2024)Third quarter 2025 results: EPS: ₹18.28 (up from ₹15.44 in 3Q 2024). Revenue: ₹4.93b (up 13% from 3Q 2024). Net income: ₹1.39b (up 19% from 3Q 2024). Profit margin: 28% (up from 27% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 31Caplin Point Laboratories Limited to Report Q3, 2025 Results on Feb 07, 2025Caplin Point Laboratories Limited announced that they will report Q3, 2025 results on Feb 07, 2025分析記事 • Jan 28Some Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Shareholders Look For Exit As Shares Take 27% PoundingThe Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) share price has softened a substantial 27% over the previous...お知らせ • Jan 07Caplin Point Laboratories Ltd. Receives Establishment Inspection Report from the U.S. Food and Drug AdministrationCaplin Point Laboratories Ltd. announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the recent inspection conducted at Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi. The unannounced USFDA inspection was conducted between August 5th and 9th, 2024 and was concluded with Zero 483 observations, reflecting the company's commitment to maintaining the higher standards of quality and compliance. This follows the intimation made to the Stock Exchanges on August 9th, 2024 immediately upon completion of the inspection about its outcome. The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.分析記事 • Dec 01Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is LackingIt's not a stretch to say that Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...分析記事 • Nov 10₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These ResultsAs you might know, Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently reported its quarterly numbers. It was...お知らせ • Nov 08Caplin Point Laboratories Limited Announces Cessation of D Sathyanarayanan as an Independent DirectorCaplin Point Laboratories Limited announced that Mr. D Sathyanarayanan's term as an Independent Director of the Company had ceased with effect from the close of business hours of November 08, 2024 in accordance with the terms of his appointment and as he had served the maximum tenure permitted for an Independent Director.Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: ₹17.22 (vs ₹15.13 in 2Q 2024)Second quarter 2025 results: EPS: ₹17.22 (up from ₹15.13 in 2Q 2024). Revenue: ₹5.04b (up 23% from 2Q 2024). Net income: ₹1.31b (up 14% from 2Q 2024). Profit margin: 26% (down from 28% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 31Caplin Point Laboratories Limited to Report Q2, 2025 Results on Nov 07, 2024Caplin Point Laboratories Limited announced that they will report Q2, 2025 results on Nov 07, 2024分析記事 • Oct 31With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting CaseInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Price Target Changed • Oct 11Price target increased by 14% to ₹2,142Up from ₹1,883, the current price target is an average from 3 analysts. New target price is 12% above last closing price of ₹1,906. Stock is up 72% over the past year. The company is forecast to post earnings per share of ₹67.78 for next year compared to ₹60.19 last year.Upcoming Dividend • Sep 16Upcoming dividend of ₹2.50 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 8.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%).分析記事 • Sep 12Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will pay a dividend on the 30th...New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹2,120, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 130% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹871 per share.Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹1,846, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 166% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹871 per share.分析記事 • Aug 11Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764Shareholders might have noticed that Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) filed its quarterly result...分析記事 • Aug 10Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will pay a dividend of ₹2.50...Price Target Changed • Aug 09Price target increased by 17% to ₹1,717Up from ₹1,472, the current price target is an average from 3 analysts. New target price is 14% above last closing price of ₹1,501. Stock is up 45% over the past year. The company is forecast to post earnings per share of ₹64.00 for next year compared to ₹60.19 last year.Declared Dividend • Aug 09Dividend of ₹2.50 announcedDividend of ₹2.50 is the same as last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (9% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 26% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 11% over the next year, which should provide support to the dividend and adequate earnings cover.お知らせ • Aug 08Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024Caplin Point Laboratories Limited at its board meeting held on August 7, 2024, recommended a Final Dividend of INR 2.5 (125%) per equity share of INR 2 each for the financial year ended March 31, 2024. This shall be paid subject To Approve the shareholders at the upcoming Annual General Meeting.Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: ₹16.32 (vs ₹13.62 in 1Q 2024)First quarter 2025 results: EPS: ₹16.32 (up from ₹13.62 in 1Q 2024). Revenue: ₹4.78b (up 21% from 1Q 2024). Net income: ₹1.24b (up 20% from 1Q 2024). Profit margin: 26% (in line with 1Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year and the company’s share price has also increased by 20% per year.お知らせ • Aug 07Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024.お知らせ • Jul 31Caplin Point Laboratories Limited to Report Q1, 2025 Results on Aug 07, 2024Caplin Point Laboratories Limited announced that they will report Q1, 2025 results on Aug 07, 2024分析記事 • Jul 12Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) EarningsCaplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E") ratio of 25.2x might make it look...お知らせ • Jun 13Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital OfficerCaplin Point Laboratories Limited announced the appointment of Mr. Thiagaraja Manikandan as Chief Transformation & Digital Officer with effect from June 11, 2024. He will be responsible for overseeing the Company's digital initiatives. Term: Full-time employment. With over three decades of leadership experience, Mr. Thiagaraja Manikandan has spearheaded digital transformations in a wide spectrum of industries, spanning from food and agribusiness to manufacturing, retail, CPG, global logistics, direct marketing consumer durables, and media. He is expert in both B2B and B2C business environments.Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹1,459, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 118% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹979 per share.分析記事 • May 24Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying IssuesCaplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) robust recent earnings didn't do much to move the stock. However...Reported Earnings • May 18Full year 2024 earnings: Revenues in line with analyst expectationsFull year 2024 results: Revenue: ₹17.6b (up 20% from FY 2023). Net income: ₹4.57b (up 22% from FY 2023). Profit margin: 26% (in line with FY 2023). Revenue was in line with analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.お知らせ • May 17Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024Caplin Point Laboratories Limited announced that at its board meeting held on May 16, 2024, declared an interim dividend of INR. 2.5 (125%) per equity share of face value of INR 2 each for the financial year ended March 31, 2024. Fixed May 31,2024 as record date for determining the eligibility of the shareholders for the purpose of interim dividend.お知らせ • May 11Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024Caplin Point Laboratories Limited announced that they will report fiscal year 2024 results at 12:15 PM, Indian Standard Time on May 16, 2024分析記事 • May 04Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Mar 07Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For ExcitementWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 31x, you may consider Caplin...Reported Earnings • Feb 10Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)Third quarter 2024 results: EPS: ₹15.44 (up from ₹12.86 in 3Q 2023). Revenue: ₹4.53b (up 22% from 3Q 2023). Net income: ₹1.17b (up 20% from 3Q 2023). Profit margin: 26% (in line with 3Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 31Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024Caplin Point Laboratories Limited announced that they will report Q3, 2024 results on Feb 09, 2024Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,285, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 174% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹696 per share.Price Target Changed • Nov 13Price target increased by 8.0% to ₹1,076Up from ₹996, the current price target is an average from 3 analysts. New target price is 17% below last closing price of ₹1,293. Stock is up 67% over the past year. The company is forecast to post earnings per share of ₹59.70 for next year compared to ₹49.62 last year.Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)Second quarter 2024 results: EPS: ₹15.13 (up from ₹12.09 in 2Q 2023). Revenue: ₹4.30b (up 20% from 2Q 2023). Net income: ₹1.15b (up 25% from 2Q 2023). Profit margin: 27% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 02Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023Caplin Point Laboratories Limited announced that they will report Q2, 2024 results on Nov 09, 2023分析記事 • Oct 24With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...お知らせ • Sep 23Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023Caplin Point Laboratories Limited at the AGM held on September 21, 2023 approved to declare final dividend of INR 2.5 (125%) per equity share of INR 2 as recommended by the Board of Directors of the company and to ratify the Interim Dividend of INR 2 (10 %) per equity share of INR 2 aggregating to INR 4.5 (225%) for the year ended March 31,2023.分析記事 • Sep 15Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay RiseKey Insights Caplin Point Laboratories will host its Annual General Meeting on 21st of September CEO Sridhar Ganesan's...Upcoming Dividend • Sep 07Upcoming dividend of ₹2.50 per share at 0.5% yieldEligible shareholders must have bought the stock before 14 September 2023. Payment date: 21 October 2023. Payout ratio is a comfortable 9.1% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.9%).お知らせ • Aug 31Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023, at 10:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2023 along with the Reports of the Board of Director's and the Auditor's thereon; to consider declaration of Final Dividend and ratification of Interim Dividend; to re-appoint Mr. C. C. Paarthipan who retires by rotation, and being eligible, offers himself for re-appointment; and to consider other matters.Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹1,032, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹579 per share.分析記事 • Aug 11Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) dividend will be increasing from last year's payment of the same...お知らせ • Aug 09Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023Caplin Point Laboratories Limited at its board meeting held on August 7, 2023, Recommended a Final Dividend of INR. 2.5 (125%) per equity share of INR 2 each for the financial year ended March 31, 2023. This shall be subject to approval of the shareholders at the forthcoming Annual General Meeting.Reported Earnings • Aug 08First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)First quarter 2024 results: EPS: ₹13.62 (up from ₹11.21 in 1Q 2023). Revenue: ₹3.95b (up 14% from 1Q 2023). Net income: ₹1.03b (up 22% from 1Q 2023). Profit margin: 26% (up from 25% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year.お知らせ • Aug 01Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023Caplin Point Laboratories Limited announced that they will report Q1, 2024 results on Aug 07, 2023お知らせ • Jun 13Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USPCaplin Steriles Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP, 10 mg/5 mL (2 mg/mL) and 200 mg/20 mL (10 mg/mL) Single-dose Vials; and 20 mg/10 mL (2 mg/mL). Multiple-dose Vials (Preserved)., a generic therapeutic equivalent version of (RLD), NIMBEX injection of AbbVie Inc. Cisatracurium besylate Injection USP is a nondepolarizing skeletal neuromuscular blocker, indicated as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgical procedures. According to IQVIATM (IMS Health), Cisatracuriumesylate Injection USP had US sales of approximately $35 million for the 12-month period ending December 2022.Upcoming Dividend • Jun 02Upcoming dividend of ₹2.00 per share at 0.3% yieldEligible shareholders must have bought the stock before 09 June 2023. Payment date: 26 August 2023. Payout ratio is a comfortable 4.0% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%).Reported Earnings • May 30Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: ₹49.62 (up from ₹39.61 in FY 2022). Revenue: ₹15.2b (up 20% from FY 2022). Net income: ₹3.76b (up 26% from FY 2022). Profit margin: 25% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 14Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023Caplin Point Laboratories Limited announced that they will report Q4, 2023 results on May 24, 2023Buying Opportunity • Mar 24Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 15%. The fair value is estimated to be ₹750, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 14% in the next 2 years.Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)Third quarter 2023 results: EPS: ₹12.86 (up from ₹9.90 in 3Q 2022). Revenue: ₹3.86b (up 18% from 3Q 2022). Net income: ₹974.8m (up 30% from 3Q 2022). Profit margin: 25% (up from 23% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 29Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023Caplin Point Laboratories Limited announced that they will report Q3, 2023 results on Feb 11, 2023Price Target Changed • Nov 16Price target increased to ₹948Up from ₹678, the current price target is an average from 3 analysts. New target price is 26% above last closing price of ₹751. Stock is down 13% over the past year. The company is forecast to post earnings per share of ₹44.30 for next year compared to ₹39.61 last year.Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)Second quarter 2023 results: EPS: ₹12.09 (up from ₹9.91 in 2Q 2022). Revenue: ₹3.76b (up 24% from 2Q 2022). Net income: ₹916.7m (up 22% from 2Q 2022). Profit margin: 24% (in line with 2Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 23We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay RiseThe impressive results at Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently will be great news for...Upcoming Dividend • Sep 14Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 21 September 2022. Payment date: 29 October 2022. Payout ratio is a comfortable 9.7% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%).分析記事 • Sep 11Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last YearThe board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will be paying its dividend of...Reported Earnings • Aug 06First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)First quarter 2023 results: EPS: ₹11.21 (up from ₹9.37 in 1Q 2022). Revenue: ₹3.60b (up 20% from 1Q 2022). Net income: ₹849.9m (up 20% from 1Q 2022). Profit margin: 24% (in line with 1Q 2022). Over the next year, revenue is forecast to grow 16%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jul 22Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • May 19Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹801, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹375 per share.Upcoming Dividend • May 16Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 23 May 2022. Payment date: 11 June 2022. Payout ratio is a comfortable 8.8% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%).Reported Earnings • May 15Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: EPS: ₹39.61 (up from ₹32.03 in FY 2021). Net income: ₹3.00b (up 24% from FY 2021). Post-clinical trial products Approved (during full year): 1 Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 15Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that the dividend on 11th of June will...Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non-Executive Independent Director Chanderkanta Gariyali was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 04Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹9.90 (up from ₹8.52 in 3Q 2021). Revenue: ₹3.36b (up 22% from 3Q 2021). Net income: ₹749.5m (up 16% from 3Q 2021). Profit margin: 22% (down from 24% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 12%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jan 21A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)Today we will run through one way of estimating the intrinsic value of Caplin Point Laboratories Limited...Board Change • Dec 06Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Chanderkanta Gariyali was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.業績と収益の成長予測NSEI:CAPLIPOINT - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202828,0538,1255,4137,66323/31/202724,8807,1285,5017,57923/31/202621,8726,4122,7515,232N/A12/31/202520,9166,137N/AN/AN/A9/30/202520,4185,8882,9215,003N/A6/30/202519,8875,651N/AN/AN/A3/31/202519,3965,3632,4094,324N/A12/31/202418,9035,153N/AN/AN/A9/30/202418,3284,9362,3103,748N/A6/30/202417,5774,776N/AN/AN/A3/31/202416,9614,5711,7263,184N/A12/31/202316,3184,376N/AN/AN/A9/30/202315,6834,1793992,593N/A6/30/202315,1573,947N/AN/AN/A3/31/202314,6833,7637792,714N/A12/31/202214,1823,532N/AN/AN/A9/30/202213,7243,3072,3053,467N/A6/30/202213,1533,140N/AN/AN/A3/31/202212,7102,9982,4563,367N/A12/31/202112,0992,872N/AN/AN/A9/30/202111,5812,7671,2882,044N/A6/30/202111,2172,586N/AN/AN/A3/31/202110,6242,4231,9532,686N/A12/31/20209,9862,248N/AN/AN/A9/30/20209,5242,1891,6501,877N/A6/30/20209,1072,193N/AN/AN/A3/31/20208,6402,150-321447N/A12/31/20198,3562,159N/AN/AN/A9/30/20197,6642,032N/A830N/A6/30/20196,9481,894N/AN/AN/A3/31/20196,4901,766N/A834N/A12/31/20186,0481,621N/AN/AN/A9/30/20185,8741,538N/AN/AN/A6/30/20185,6281,459N/AN/AN/A3/31/20185,3991,448N/A665N/A12/31/20175,1451,430N/AN/AN/A9/30/20174,7571,297N/AN/AN/A6/30/20174,4011,165N/AN/AN/A3/31/20174,016956N/A676N/A12/31/20163,655783N/AN/AN/A9/30/20163,420703N/AN/AN/A6/30/20163,238619N/AN/AN/A3/31/20163,088584N/A565N/A12/31/20152,906535N/AN/AN/A9/30/20152,722465N/AN/AN/A6/30/20152,518410N/A499N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CAPLIPOINTの予測収益成長率 (年間11.8% ) は 貯蓄率 ( 6.9% ) を上回っています。収益対市場: CAPLIPOINTの収益 ( 11.8% ) Indian市場 ( 16.2% ) よりも低い成長が予測されています。高成長収益: CAPLIPOINTの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: CAPLIPOINTの収益 ( 12.4% ) Indian市場 ( 10.8% ) よりも速いペースで成長すると予測されています。高い収益成長: CAPLIPOINTの収益 ( 12.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CAPLIPOINTの 自己資本利益率 は、3年後には低くなると予測されています ( 17 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/05 05:44終値2026/06/05 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Caplin Point Laboratories Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedSiddhant KhandekarICICIdirect.com
分析記事 • May 18Earnings Update: Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Just Reported Its Annual Results And Analysts Are Updating Their ForecastsIt's been a good week for Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) shareholders, because the company has...
分析記事 • Nov 10₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These ResultsAs you might know, Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently reported its quarterly numbers. It was...
Price Target Changed • Oct 11Price target increased by 14% to ₹2,142Up from ₹1,883, the current price target is an average from 3 analysts. New target price is 12% above last closing price of ₹1,906. Stock is up 72% over the past year. The company is forecast to post earnings per share of ₹67.78 for next year compared to ₹60.19 last year.
分析記事 • Aug 11Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764Shareholders might have noticed that Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) filed its quarterly result...
Price Target Changed • Aug 09Price target increased by 17% to ₹1,717Up from ₹1,472, the current price target is an average from 3 analysts. New target price is 14% above last closing price of ₹1,501. Stock is up 45% over the past year. The company is forecast to post earnings per share of ₹64.00 for next year compared to ₹60.19 last year.
Price Target Changed • Nov 13Price target increased by 8.0% to ₹1,076Up from ₹996, the current price target is an average from 3 analysts. New target price is 17% below last closing price of ₹1,293. Stock is up 67% over the past year. The company is forecast to post earnings per share of ₹59.70 for next year compared to ₹49.62 last year.
Declared Dividend • May 16Final dividend increased to ₹4.00Dividend of ₹4.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 13th June 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (4% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 15Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: ₹84.36 (up from ₹70.57 in FY 2025). Revenue: ₹23.0b (up 19% from FY 2025). Net income: ₹6.41b (up 20% from FY 2025). Profit margin: 28% (in line with FY 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 3.7%. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 07Caplin Point Laboratories Limited to Report Q4, 2026 Results on May 14, 2026Caplin Point Laboratories Limited announced that they will report Q4, 2026 results on May 14, 2026
分析記事 • Feb 12Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Share Price Not Quite Adding UpIt's not a stretch to say that Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...
Board Change • Feb 10High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-executive Independent Director Susan Mathew was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹21.56 (vs ₹18.28 in 3Q 2025)Third quarter 2026 results: EPS: ₹21.56 (up from ₹18.28 in 3Q 2025). Revenue: ₹5.76b (up 17% from 3Q 2025). Net income: ₹1.64b (up 18% from 3Q 2025). Profit margin: 28% (in line with 3Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 27Caplin Point Laboratories Limited to Report Q3, 2026 Results on Feb 05, 2026Caplin Point Laboratories Limited announced that they will report Q3, 2026 results on Feb 05, 2026
分析記事 • Dec 05Do Caplin Point Laboratories' (NSE:CAPLIPOINT) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
分析記事 • Nov 09Getting In Cheap On Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is UnlikelyThere wouldn't be many who think Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...
Reported Earnings • Nov 06Second quarter 2026 earnings released: EPS: ₹20.32 (vs ₹17.22 in 2Q 2025)Second quarter 2026 results: EPS: ₹20.32 (up from ₹17.22 in 2Q 2025). Revenue: ₹5.64b (up 17% from 2Q 2025). Net income: ₹1.54b (up 18% from 2Q 2025). Profit margin: 27% (in line with 2Q 2025). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 29Caplin Point Laboratories Limited to Report Q2, 2026 Results on Nov 05, 2025Caplin Point Laboratories Limited announced that they will report Q2, 2026 results on Nov 05, 2025
分析記事 • Sep 16We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay RiseKey Insights Caplin Point Laboratories will host its Annual General Meeting on 22nd of September CEO Sridhar Ganesan's...
Upcoming Dividend • Sep 05Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 12 September 2025. Payment date: 21 October 2025. Payout ratio is a comfortable 8.5% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%).
分析記事 • Aug 31Do Caplin Point Laboratories' (NSE:CAPLIPOINT) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Declared Dividend • Aug 09Dividend of ₹3.00 announcedShareholders will receive a dividend of ₹3.00. Ex-date: 12th September 2025 Payment date: 21st October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (8% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 17% over the next year, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Aug 08First quarter 2026 earnings released: EPS: ₹20.10 (vs ₹16.32 in 1Q 2025)First quarter 2026 results: EPS: ₹20.10 (up from ₹16.32 in 1Q 2025). Revenue: ₹5.33b (up 16% from 1Q 2025). Net income: ₹1.53b (up 23% from 1Q 2025). Profit margin: 29% (up from 27% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 07Caplin Point Laboratories Limited, Annual General Meeting, Sep 22, 2025Caplin Point Laboratories Limited, Annual General Meeting, Sep 22, 2025.
分析記事 • Aug 06Earnings Not Telling The Story For Caplin Point Laboratories Limited (NSE:CAPLIPOINT)NSEI:CAPLIPOINT 1 Year Share Price vs Fair Value Explore Caplin Point Laboratories's Fair Values from the Community and...
お知らせ • Jul 30Caplin Point Laboratories Limited to Report Q1, 2026 Results on Aug 07, 2025Caplin Point Laboratories Limited announced that they will report Q1, 2026 results on Aug 07, 2025
分析記事 • May 18Earnings Update: Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Just Reported Its Annual Results And Analysts Are Updating Their ForecastsIt's been a good week for Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) shareholders, because the company has...
Declared Dividend • May 17Final dividend of ₹3.00 announcedShareholders will receive a dividend of ₹3.00. Ex-date: 30th May 2025 Payment date: 14th June 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (4% earnings payout ratio) and cash flows (16% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 35% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 16Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: EPS: ₹70.57 (up from ₹60.20 in FY 2024). Revenue: ₹20.3b (up 20% from FY 2024). Net income: ₹5.36b (up 17% from FY 2024). Profit margin: 26% (in line with FY 2024). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 2.1%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 10Caplin Point Laboratories Limited to Report Fiscal Year 2025 Results on May 15, 2025Caplin Point Laboratories Limited announced that they will report fiscal year 2025 results on May 15, 2025
お知らせ • Apr 22Caplin Point Laboratories Limited Announces Resignation of Thiagaraja Manikandan as Chief Transformation & Digital Officer, A Senior Management Personnel, Effective April 21, 2025Caplin Point Laboratories Limited announced that Mr. Thiagaraja Manikandan, Chief Transformation & Digital Officer, a Senior Management Personnel (SMP) of the Company, has resigned with effect from the close of working hours of April 21, 2025.
分析記事 • Apr 14With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting CaseInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Apr 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹1,714, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 126% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹1,268 per share.
Reported Earnings • Feb 08Third quarter 2025 earnings released: EPS: ₹18.28 (vs ₹15.44 in 3Q 2024)Third quarter 2025 results: EPS: ₹18.28 (up from ₹15.44 in 3Q 2024). Revenue: ₹4.93b (up 13% from 3Q 2024). Net income: ₹1.39b (up 19% from 3Q 2024). Profit margin: 28% (up from 27% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 31Caplin Point Laboratories Limited to Report Q3, 2025 Results on Feb 07, 2025Caplin Point Laboratories Limited announced that they will report Q3, 2025 results on Feb 07, 2025
分析記事 • Jan 28Some Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Shareholders Look For Exit As Shares Take 27% PoundingThe Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) share price has softened a substantial 27% over the previous...
お知らせ • Jan 07Caplin Point Laboratories Ltd. Receives Establishment Inspection Report from the U.S. Food and Drug AdministrationCaplin Point Laboratories Ltd. announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the recent inspection conducted at Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi. The unannounced USFDA inspection was conducted between August 5th and 9th, 2024 and was concluded with Zero 483 observations, reflecting the company's commitment to maintaining the higher standards of quality and compliance. This follows the intimation made to the Stock Exchanges on August 9th, 2024 immediately upon completion of the inspection about its outcome. The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
分析記事 • Dec 01Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is LackingIt's not a stretch to say that Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E...
分析記事 • Nov 10₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These ResultsAs you might know, Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently reported its quarterly numbers. It was...
お知らせ • Nov 08Caplin Point Laboratories Limited Announces Cessation of D Sathyanarayanan as an Independent DirectorCaplin Point Laboratories Limited announced that Mr. D Sathyanarayanan's term as an Independent Director of the Company had ceased with effect from the close of business hours of November 08, 2024 in accordance with the terms of his appointment and as he had served the maximum tenure permitted for an Independent Director.
Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: ₹17.22 (vs ₹15.13 in 2Q 2024)Second quarter 2025 results: EPS: ₹17.22 (up from ₹15.13 in 2Q 2024). Revenue: ₹5.04b (up 23% from 2Q 2024). Net income: ₹1.31b (up 14% from 2Q 2024). Profit margin: 26% (down from 28% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 31Caplin Point Laboratories Limited to Report Q2, 2025 Results on Nov 07, 2024Caplin Point Laboratories Limited announced that they will report Q2, 2025 results on Nov 07, 2024
分析記事 • Oct 31With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting CaseInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Price Target Changed • Oct 11Price target increased by 14% to ₹2,142Up from ₹1,883, the current price target is an average from 3 analysts. New target price is 12% above last closing price of ₹1,906. Stock is up 72% over the past year. The company is forecast to post earnings per share of ₹67.78 for next year compared to ₹60.19 last year.
Upcoming Dividend • Sep 16Upcoming dividend of ₹2.50 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 8.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%).
分析記事 • Sep 12Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will pay a dividend on the 30th...
New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹2,120, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 130% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹871 per share.
Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹1,846, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 166% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹871 per share.
分析記事 • Aug 11Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764Shareholders might have noticed that Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) filed its quarterly result...
分析記事 • Aug 10Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will pay a dividend of ₹2.50...
Price Target Changed • Aug 09Price target increased by 17% to ₹1,717Up from ₹1,472, the current price target is an average from 3 analysts. New target price is 14% above last closing price of ₹1,501. Stock is up 45% over the past year. The company is forecast to post earnings per share of ₹64.00 for next year compared to ₹60.19 last year.
Declared Dividend • Aug 09Dividend of ₹2.50 announcedDividend of ₹2.50 is the same as last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (9% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 26% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 11% over the next year, which should provide support to the dividend and adequate earnings cover.
お知らせ • Aug 08Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024Caplin Point Laboratories Limited at its board meeting held on August 7, 2024, recommended a Final Dividend of INR 2.5 (125%) per equity share of INR 2 each for the financial year ended March 31, 2024. This shall be paid subject To Approve the shareholders at the upcoming Annual General Meeting.
Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: ₹16.32 (vs ₹13.62 in 1Q 2024)First quarter 2025 results: EPS: ₹16.32 (up from ₹13.62 in 1Q 2024). Revenue: ₹4.78b (up 21% from 1Q 2024). Net income: ₹1.24b (up 20% from 1Q 2024). Profit margin: 26% (in line with 1Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year and the company’s share price has also increased by 20% per year.
お知らせ • Aug 07Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024.
お知らせ • Jul 31Caplin Point Laboratories Limited to Report Q1, 2025 Results on Aug 07, 2024Caplin Point Laboratories Limited announced that they will report Q1, 2025 results on Aug 07, 2024
分析記事 • Jul 12Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) EarningsCaplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) price-to-earnings (or "P/E") ratio of 25.2x might make it look...
お知らせ • Jun 13Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital OfficerCaplin Point Laboratories Limited announced the appointment of Mr. Thiagaraja Manikandan as Chief Transformation & Digital Officer with effect from June 11, 2024. He will be responsible for overseeing the Company's digital initiatives. Term: Full-time employment. With over three decades of leadership experience, Mr. Thiagaraja Manikandan has spearheaded digital transformations in a wide spectrum of industries, spanning from food and agribusiness to manufacturing, retail, CPG, global logistics, direct marketing consumer durables, and media. He is expert in both B2B and B2C business environments.
Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹1,459, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 118% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹979 per share.
分析記事 • May 24Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying IssuesCaplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) robust recent earnings didn't do much to move the stock. However...
Reported Earnings • May 18Full year 2024 earnings: Revenues in line with analyst expectationsFull year 2024 results: Revenue: ₹17.6b (up 20% from FY 2023). Net income: ₹4.57b (up 22% from FY 2023). Profit margin: 26% (in line with FY 2023). Revenue was in line with analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.
お知らせ • May 17Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024Caplin Point Laboratories Limited announced that at its board meeting held on May 16, 2024, declared an interim dividend of INR. 2.5 (125%) per equity share of face value of INR 2 each for the financial year ended March 31, 2024. Fixed May 31,2024 as record date for determining the eligibility of the shareholders for the purpose of interim dividend.
お知らせ • May 11Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024Caplin Point Laboratories Limited announced that they will report fiscal year 2024 results at 12:15 PM, Indian Standard Time on May 16, 2024
分析記事 • May 04Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
分析記事 • Mar 07Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For ExcitementWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 31x, you may consider Caplin...
Reported Earnings • Feb 10Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)Third quarter 2024 results: EPS: ₹15.44 (up from ₹12.86 in 3Q 2023). Revenue: ₹4.53b (up 22% from 3Q 2023). Net income: ₹1.17b (up 20% from 3Q 2023). Profit margin: 26% (in line with 3Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 31Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024Caplin Point Laboratories Limited announced that they will report Q3, 2024 results on Feb 09, 2024
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,285, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 174% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹696 per share.
Price Target Changed • Nov 13Price target increased by 8.0% to ₹1,076Up from ₹996, the current price target is an average from 3 analysts. New target price is 17% below last closing price of ₹1,293. Stock is up 67% over the past year. The company is forecast to post earnings per share of ₹59.70 for next year compared to ₹49.62 last year.
Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)Second quarter 2024 results: EPS: ₹15.13 (up from ₹12.09 in 2Q 2023). Revenue: ₹4.30b (up 20% from 2Q 2023). Net income: ₹1.15b (up 25% from 2Q 2023). Profit margin: 27% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 02Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023Caplin Point Laboratories Limited announced that they will report Q2, 2024 results on Nov 09, 2023
分析記事 • Oct 24With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
お知らせ • Sep 23Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023Caplin Point Laboratories Limited at the AGM held on September 21, 2023 approved to declare final dividend of INR 2.5 (125%) per equity share of INR 2 as recommended by the Board of Directors of the company and to ratify the Interim Dividend of INR 2 (10 %) per equity share of INR 2 aggregating to INR 4.5 (225%) for the year ended March 31,2023.
分析記事 • Sep 15Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay RiseKey Insights Caplin Point Laboratories will host its Annual General Meeting on 21st of September CEO Sridhar Ganesan's...
Upcoming Dividend • Sep 07Upcoming dividend of ₹2.50 per share at 0.5% yieldEligible shareholders must have bought the stock before 14 September 2023. Payment date: 21 October 2023. Payout ratio is a comfortable 9.1% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.9%).
お知らせ • Aug 31Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023, at 10:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2023 along with the Reports of the Board of Director's and the Auditor's thereon; to consider declaration of Final Dividend and ratification of Interim Dividend; to re-appoint Mr. C. C. Paarthipan who retires by rotation, and being eligible, offers himself for re-appointment; and to consider other matters.
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹1,032, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹579 per share.
分析記事 • Aug 11Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50Caplin Point Laboratories Limited's ( NSE:CAPLIPOINT ) dividend will be increasing from last year's payment of the same...
お知らせ • Aug 09Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023Caplin Point Laboratories Limited at its board meeting held on August 7, 2023, Recommended a Final Dividend of INR. 2.5 (125%) per equity share of INR 2 each for the financial year ended March 31, 2023. This shall be subject to approval of the shareholders at the forthcoming Annual General Meeting.
Reported Earnings • Aug 08First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)First quarter 2024 results: EPS: ₹13.62 (up from ₹11.21 in 1Q 2023). Revenue: ₹3.95b (up 14% from 1Q 2023). Net income: ₹1.03b (up 22% from 1Q 2023). Profit margin: 26% (up from 25% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year.
お知らせ • Aug 01Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023Caplin Point Laboratories Limited announced that they will report Q1, 2024 results on Aug 07, 2023
お知らせ • Jun 13Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USPCaplin Steriles Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP, 10 mg/5 mL (2 mg/mL) and 200 mg/20 mL (10 mg/mL) Single-dose Vials; and 20 mg/10 mL (2 mg/mL). Multiple-dose Vials (Preserved)., a generic therapeutic equivalent version of (RLD), NIMBEX injection of AbbVie Inc. Cisatracurium besylate Injection USP is a nondepolarizing skeletal neuromuscular blocker, indicated as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgical procedures. According to IQVIATM (IMS Health), Cisatracuriumesylate Injection USP had US sales of approximately $35 million for the 12-month period ending December 2022.
Upcoming Dividend • Jun 02Upcoming dividend of ₹2.00 per share at 0.3% yieldEligible shareholders must have bought the stock before 09 June 2023. Payment date: 26 August 2023. Payout ratio is a comfortable 4.0% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%).
Reported Earnings • May 30Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: ₹49.62 (up from ₹39.61 in FY 2022). Revenue: ₹15.2b (up 20% from FY 2022). Net income: ₹3.76b (up 26% from FY 2022). Profit margin: 25% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 14Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023Caplin Point Laboratories Limited announced that they will report Q4, 2023 results on May 24, 2023
Buying Opportunity • Mar 24Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 15%. The fair value is estimated to be ₹750, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 14% in the next 2 years.
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)Third quarter 2023 results: EPS: ₹12.86 (up from ₹9.90 in 3Q 2022). Revenue: ₹3.86b (up 18% from 3Q 2022). Net income: ₹974.8m (up 30% from 3Q 2022). Profit margin: 25% (up from 23% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 29Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023Caplin Point Laboratories Limited announced that they will report Q3, 2023 results on Feb 11, 2023
Price Target Changed • Nov 16Price target increased to ₹948Up from ₹678, the current price target is an average from 3 analysts. New target price is 26% above last closing price of ₹751. Stock is down 13% over the past year. The company is forecast to post earnings per share of ₹44.30 for next year compared to ₹39.61 last year.
Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)Second quarter 2023 results: EPS: ₹12.09 (up from ₹9.91 in 2Q 2022). Revenue: ₹3.76b (up 24% from 2Q 2022). Net income: ₹916.7m (up 22% from 2Q 2022). Profit margin: 24% (in line with 2Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 23We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay RiseThe impressive results at Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) recently will be great news for...
Upcoming Dividend • Sep 14Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 21 September 2022. Payment date: 29 October 2022. Payout ratio is a comfortable 9.7% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%).
分析記事 • Sep 11Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last YearThe board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that it will be paying its dividend of...
Reported Earnings • Aug 06First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)First quarter 2023 results: EPS: ₹11.21 (up from ₹9.37 in 1Q 2022). Revenue: ₹3.60b (up 20% from 1Q 2022). Net income: ₹849.9m (up 20% from 1Q 2022). Profit margin: 24% (in line with 1Q 2022). Over the next year, revenue is forecast to grow 16%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jul 22Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • May 19Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹801, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹375 per share.
Upcoming Dividend • May 16Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 23 May 2022. Payment date: 11 June 2022. Payout ratio is a comfortable 8.8% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%).
Reported Earnings • May 15Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: EPS: ₹39.61 (up from ₹32.03 in FY 2021). Net income: ₹3.00b (up 24% from FY 2021). Post-clinical trial products Approved (during full year): 1 Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 15Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00The board of Caplin Point Laboratories Limited ( NSE:CAPLIPOINT ) has announced that the dividend on 11th of June will...
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non-Executive Independent Director Chanderkanta Gariyali was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 04Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹9.90 (up from ₹8.52 in 3Q 2021). Revenue: ₹3.36b (up 22% from 3Q 2021). Net income: ₹749.5m (up 16% from 3Q 2021). Profit margin: 22% (down from 24% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 12%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jan 21A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)Today we will run through one way of estimating the intrinsic value of Caplin Point Laboratories Limited...
Board Change • Dec 06Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Chanderkanta Gariyali was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.